Takeda’s Post

An illuminating read from Rick Ascroft, head of U.S. Plasma-Derived Therapies Business Unit, about #CIDP management and the opportunity we have through our work each day to improve patient outcomes. So important to elevate awareness of this and other #RareDiseases. #TeamTakeda

How do Physicians consider and ultimately prescribe a therapy for a patient diagnosed with Multiple Sclerosis? There are many market research/syndicated studies that aid in understanding the performance of a particular therapy in a disease area - RxY stands out as the only syndicated study to support the true why / why not - behind physician treatment choices for dynamic patients.  At RxY, we purposefully design our patient chart audit in order to bridge the qualitative-quantitative gap and address this question. The RxY Multiple Sclerosis patient chart audit includes: • Focusing on Dynamic Patients - initiations and switches. Understanding the true why/why not for-why a physician considers and prescribes a therapy. This allows our clients to win greater patient shares, by making data driven decisions that optimize marketing strategies. • Collection and analysis of the following number of Dynamic Patient charts within the Multiple Sclerosis therapeutic area: o USA - 7,937 since 2020 o EU5 - 5,944 since 2021 o Japan - 715 in 2023 o Brazil - 270 in 2023 • Treatment decision verbatims collected from physicians on the true why / why not o USA - 39,685 o EU - 29,720 o Japan - 3,575 o Brazil - 1,350 • Delivery of rich qualitative data with the confidence of robust quantitative samples If you would like to learn more about our work at RxY and see the complete list of Therapy Areas we cover, visit our website - https://lnkd.in/dsP-cHqU Please feel free to contact me directly if you have any questions molly.feda@rxyhc.com

The risk of over diagnosis is too great already. This would only make it worse. "...In a response, the American Geriatrics Society has said that expanding the definition of Alzheimer’s in such a way could risk overdiagnosis, which 'could lead to initiation of treatments with limited benefit and high potential for harm.' "Older adults with a dementia diagnosis might additionally face discrimination from employers or insurers..." (Source: https://lnkd.in/geqXW__h) A warning was issued in 2012: "...the cumulative burden from overdiagnosis poses a significant threat to human health..." (See reference to complete study in comment.) #prevention #overdiagnosis #dementia #alzheimers #geriatrics #gerontology #employers #insurers #healthcare

We need better access to non-pharmacologic treatments. Payers need to step up coverage for what we now know is best practice for pain. Non-pharmacologic care is most comprehensively provided by Chiropractors and Physical Therapists. #spinecarepartners #physical therapy

🌟 Innovator Spotlight Series, Part 3: Transforming Opioid Care with Carenostics    As we conclude our Innovator Spotlight Series on opioid safety, we delve into the groundbreaking collaboration between Carenostics and the VA Pittsburgh Healthcare System (VAPHS), leveraging AI to revolutionize Opioid Use Disorder (OUD) treatment. Carenostics, known for their AI-driven platform targeting chronic diseases, has extended its focus to #OUD, specifically tailoring their solution to individual health system needs.   Leveraging 23 years of treatment data, the solution integrates seamlessly with EHRs, providing alerts for PCPs to test, diagnose, treat, or refer at-risk patients. While still in its early days, this collaboration shows promise in offering comprehensive support to veterans, highlighting the potential for AI-driven solutions to usher in a more proactive era of OUD management.   As we embrace the evolving landscape of healthcare technology, our Innovator Spotlight Series emphasizes the shift from reactive interventions to early detection and prevention, presenting an opportunity to reduce overdose recurrence rates and make a lasting impact on this pervasive public health issue.   Let us know what you think in the comments below. #HealthcareInnovation #OpioidSafety #RealizingInnovationTogether  

AccendoWave - A Pain #Data Company Investigators concluded that global assessment measures in chronic #pain trials need further improvement. A Top 4 Global Health Equity Solution and Top 15 Global Remote Monitoring Company, AccendoWave, benchmarks objective brain wave pain data (specialty, gender, age) and has nine #pain databases: Emergency Department, Maternal Health, Oncology, MSK, Medical Surgical, ICU, hashtag #Women, Adults, Seniors to eliminate bias, improve outcomes and reduce health care costs. If desired, AccendoWave can also create customized pain databases for partners that can be accessed on the Datavant platform.

Primary Physicians and Pelvic Providers: Include a digital therapeutic in your treatment plan for patients with persistent pelvic pain. Many patients are challenged to find, afford or are on long wait lists for non-pharmacological therapy providers. To prevent further pain catastrophizing, depression, anxiety and pain, teach patients the value of learning pain science education and self care by using an online home program concurrently with medical care. Digital therapeutics are affordable, evidence-based software programs providing immediate access to guide patients in the knowledge and skills to lower pain and potentially improve your patient outcome. PelvicSense is a digital therapeutic for women with persistent pelvic pain. Currently in research measuring efficacy for women diagnosed with Vulvodynia, Endometriosis and PGAD. Results by Q1 2025. Article #1: Developing Digital Therapeutics for Chronic Pain in Primary Care: A Qualitative Human-Centered Design Study of Providers’ Motivations and Challenges https://lnkd.in/eVwtAmaG Article #2: Digital health in pain assessment, diagnosis, and management: Overview and perspectives. https://lnkd.in/eUETkppz

“Greater use of passive interventions for LBP was associated with elevated odds of 1-year escalation-of-care events.” Choose active care! The study underscores the significance of opting for active interventions over passive ones in managing low back pain (LBP). It reveals that a higher reliance on passive interventions correlates with an increased likelihood of experiencing escalation-of-care events within a year. These events encompass various measures such as opioid prescriptions, spinal injections, specialty care visits, and hospitalizations. Notably, patients exposed to mechanical traction and multiple passive interventions faced a significantly higher risk of escalation, whereas those receiving manual therapy and active care exhibited more favorable health outcomes. The findings emphasize the importance of a balanced and scaled approach. It also advocate for greater scrutiny in the use of passive interventions by physical therapists to mitigate the risk of adverse health consequences for individuals with LBP. I would love to see more data on significance on a diverse population. https://lnkd.in/eZt57bXH #physicaltherapy

🧠 𝐁𝐥𝐨𝐨𝐝 𝐓𝐞𝐬𝐭 𝐂𝐨𝐮𝐥𝐝 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐞 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫'𝐬 𝐅𝐢𝐠𝐡𝐭 🧠 📌𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅𝐬 𝐚𝐭 𝐘𝐨𝐮𝐫 𝐅𝐢𝐧𝐠𝐞𝐫𝐭𝐢𝐩𝐬: https://lnkd.in/eFncdXW9 (𝙐𝙨𝙚 𝘾𝙤𝙧𝙥𝙤𝙧𝙖𝙩𝙚 𝙈𝙖𝙞𝙡 𝙄𝙙 𝙛𝙤𝙧 𝙌𝙪𝙞𝙘𝙠 𝙍𝙚𝙨𝙥𝙤𝙣𝙨𝙚) 𝑰𝒎𝒂𝒈𝒊𝒏𝒆 𝒂 𝒔𝒊𝒎𝒑𝒍𝒆𝒓 𝒘𝒂𝒚 𝒕𝒐 𝒅𝒆𝒕𝒆𝒄𝒕 𝑨𝒍𝒛𝒉𝒆𝒊𝒎𝒆𝒓'𝒔 𝒅𝒊𝒔𝒆𝒂𝒔𝒆, 𝒚𝒆𝒂𝒓𝒔 𝒃𝒆𝒇𝒐𝒓𝒆 𝒔𝒚𝒎𝒑𝒕𝒐𝒎𝒔 𝒂𝒑𝒑𝒆𝒂𝒓! A groundbreaking blood test is on the horizon, offering a less invasive and potentially more accessible method for early diagnosis. This is a game-changer for millions affected by Alzheimer's. 📌𝑾𝒉𝒚 𝒊𝒔 𝒆𝒂𝒓𝒍𝒚 𝒅𝒆𝒕𝒆𝒄𝒕𝒊𝒐𝒏 𝒔𝒐 𝒊𝒎𝒑𝒐𝒓𝒕𝒂𝒏𝒕? 𝑬𝒂𝒓𝒍𝒊𝒆𝒓 𝒊𝒏𝒕𝒆𝒓𝒗𝒆𝒏𝒕𝒊𝒐𝒏: Treatments are more effective when started sooner! This blood test could give patients a head start in managing the disease. 𝑰𝒎𝒑𝒓𝒐𝒗𝒆𝒅 𝒑𝒍𝒂𝒏𝒏𝒊𝒏𝒈: Early diagnosis allows families to make informed care decisions. 𝑹𝒆𝒅𝒖𝒄𝒆𝒅 𝒉𝒆𝒂𝒍𝒕𝒉𝒄𝒂𝒓𝒆 𝒄𝒐𝒔𝒕𝒔: This test could eliminate the need for expensive procedures. 𝑭𝒂𝒔𝒕𝒆𝒓 𝒄𝒍𝒊𝒏𝒊𝒄𝒂𝒍 𝒕𝒓𝒊𝒂𝒍𝒔: It provides a simpler way to identify and monitor participants in Alzheimer's research. This is a huge step forward in the fight against Alzheimer's! It offers hope for better patient outcomes, improved quality of life, and further advancements in treatment and care. 🔵 𝑲𝒆𝒚 𝑪𝒐𝒎𝒑𝒂𝒏𝒊𝒆𝒔 𝑷𝒓𝒐𝒇𝒊𝒍𝒆𝒅 AbbVie Teva Pharmaceuticals Eisai US Janssen Pharmaceuticals, Inc. Novartis Zydus Group Sun Pharmaceutical Sdn Bhd Dr. Reddy's Laboratories AUROBINDO PHARMA LTD #Alzheimers #EarlyDetection #BloodTest #Hope #Breakthrough #Healthcare #Caregivers #Family #Research #FutureofMedicine #Alzheimer #future #innovation #health #medicine Disclaimer- I don't intend any copyright (DM me for credit & removal)

While this is news coverage from the US, I don’t think the headline really answers the question it poses. There are several reasons I think the drug is off to slow start including prelim cost, poor health system preparedness particularly imaging needs, and effectiveness vs cost-benefit. If you want to dive in, more details below…. Partly it was the extremely high cost that its predecessor Aducanumab was introduced to the market at (subsequently prices slashed and then completely discontinued) which created major sticker shock given the number of people expected to access it. Secondly, most health systems are woefully underprepared to adequately screen and manage patients on the drug given the number of imaging tests they would need to monitor for side effects - the more serious ones being ARIA which includes brain swelling or bleeding. With limited MRI machines patients would need to wait much longer than the protocol time would recommend if they even get access to them at all. We haven’t even touched on really how under prepared physicians are to diagnose appropriately that early. And lastly the window of effect is in essence to slow down memory decline by about five months. To some patients, this is a huge window of opportunity, for others the cost benefit may not be worth it.